Pulmonary hypertension in the intensive care unit after pediatric allogeneic hematopoietic stem cell transplant: incidence, risk factors, and outcomes.
Saved in:
| Title: | Pulmonary hypertension in the intensive care unit after pediatric allogeneic hematopoietic stem cell transplant: incidence, risk factors, and outcomes. |
|---|---|
| Authors: | Smith MA; Department of Pediatrics, Division of Critical Care Medicine, University of California, San Francisco, San Francisco, CA, United States., Cheng G; Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of California, San Francisco, San Francisco, CA, United States., Phelan R; Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI, United States., Brazauskas R; Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI, United States., Strom J; Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI, United States., Ahn KW; Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI, United States., Hamilton BK; Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH, United States., Peterson A; Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI, United States., Savani B; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States., Schoemans H; Department of Haematology, University Hospital Gasthuisberg, Leuven, Belgium., Schoettler ML; Children's Healthcare of Atlanta, Emory University, Atlanta, GA, United States., Sorror M; Department of Hematology-Oncology, Fred Hutchinson Cancer Center, Seattle, WA, United States., Keller RL; Department of Pediatrics, Division of Neonatology, University of California, San Francisco, San Francisco, CA, United States., Higham CS; Department of Pediatrics, Division of Allergy, Immunology, and BMT, University of California, San Francisco, San Francisco, CA, United States., Dvorak CC; Department of Pediatrics, Division of Allergy, Immunology, and BMT, University of California, San Francisco, San Francisco, CA, United States., Fineman JR; Department of Pediatrics, Division of Critical Care Medicine, University of California, San Francisco, San Francisco, CA, United States., Zinter MS; Department of Pediatrics, Division of Critical Care Medicine, University of California, San Francisco, San Francisco, CA, United States.; Department of Pediatrics, Division of Allergy, Immunology, and BMT, University of California, San Francisco, San Francisco, CA, United States. |
| Source: | Frontiers in oncology [Front Oncol] 2024 May 29; Vol. 14, pp. 1415984. Date of Electronic Publication: 2024 May 29 (Print Publication: 2024). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
